Logo image of BNTX

BIONTECH SE-ADR (BNTX) Stock Fundamental Analysis

NASDAQ:BNTX - Nasdaq - US09075V1026 - ADR - Currency: USD

98.68  -0.39 (-0.39%)

After market: 98.68 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to BNTX. BNTX was compared to 562 industry peers in the Biotechnology industry. Both the profitability and the financial health of BNTX get a neutral evaluation. Nothing too spectacular is happening here. BNTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year BNTX has reported negative net income.
BNTX had a positive operating cash flow in the past year.
BNTX had positive earnings in 4 of the past 5 years.
BNTX had a positive operating cash flow in 4 of the past 5 years.
BNTX Yearly Net Income VS EBIT VS OCF VS FCFBNTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

BNTX has a better Return On Assets (-2.95%) than 88.41% of its industry peers.
The Return On Equity of BNTX (-3.43%) is better than 90.37% of its industry peers.
Industry RankSector Rank
ROA -2.95%
ROE -3.43%
ROIC N/A
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
BNTX Yearly ROA, ROE, ROICBNTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 100 150

1.3 Margins

BNTX's Gross Margin of 84.90% is amongst the best of the industry. BNTX outperforms 87.70% of its industry peers.
In the last couple of years the Gross Margin of BNTX has remained more or less at the same level.
BNTX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.9%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
BNTX Yearly Profit, Operating, Gross MarginsBNTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

5

2. Health

2.1 Basic Checks

BNTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
BNTX has more shares outstanding than it did 1 year ago.
BNTX has more shares outstanding than it did 5 years ago.
BNTX has a worse debt/assets ratio than last year.
BNTX Yearly Shares OutstandingBNTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
BNTX Yearly Total Debt VS Total AssetsBNTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

An Altman-Z score of 6.06 indicates that BNTX is not in any danger for bankruptcy at the moment.
BNTX has a better Altman-Z score (6.06) than 81.64% of its industry peers.
BNTX has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
BNTX's Debt to Equity ratio of 0.01 is in line compared to the rest of the industry. BNTX outperforms 42.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 6.06
ROIC/WACCN/A
WACC7.12%
BNTX Yearly LT Debt VS Equity VS FCFBNTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B 20B

2.3 Liquidity

BNTX has a Current Ratio of 7.45. This indicates that BNTX is financially healthy and has no problem in meeting its short term obligations.
BNTX has a better Current ratio (7.45) than 70.59% of its industry peers.
A Quick Ratio of 7.34 indicates that BNTX has no problem at all paying its short term obligations.
BNTX has a better Quick ratio (7.34) than 70.41% of its industry peers.
Industry RankSector Rank
Current Ratio 7.45
Quick Ratio 7.34
BNTX Yearly Current Assets VS Current LiabilitesBNTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

More info and screens

4

3. Growth

3.1 Past

The earnings per share for BNTX have decreased strongly by -780.85% in the last year.
The Revenue for BNTX has decreased by -27.96% in the past year. This is quite bad
BNTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 90.73% yearly.
EPS 1Y (TTM)-780.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.06%
Revenue 1Y (TTM)-27.96%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%-2.56%

3.2 Future

The Earnings Per Share is expected to grow by 10.72% on average over the next years. This is quite good.
Based on estimates for the next years, BNTX will show a small growth in Revenue. The Revenue will grow by 5.22% on average per year.
EPS Next Y-92.43%
EPS Next 2Y-41.48%
EPS Next 3Y-22.99%
EPS Next 5Y10.72%
Revenue Next Year-22.85%
Revenue Next 2Y-8.27%
Revenue Next 3Y-5.15%
Revenue Next 5Y5.22%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
BNTX Yearly Revenue VS EstimatesBNTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
BNTX Yearly EPS VS EstimatesBNTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20 30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BNTX. In the last year negative earnings were reported.
Also next year BNTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
BNTX Price Earnings VS Forward Price EarningsBNTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BNTX Per share dataBNTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80

4.3 Compensation for Growth

A cheap valuation may be justified as BNTX's earnings are expected to decrease with -22.99% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-41.48%
EPS Next 3Y-22.99%

More info and screens

0

5. Dividend

5.1 Amount

BNTX does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIONTECH SE-ADR

NASDAQ:BNTX (5/23/2025, 9:16:27 PM)

After market: 98.68 0 (0%)

98.68

-0.39 (-0.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-05 2025-05-05/bmo
Earnings (Next)08-04 2025-08-04/bmo
Inst Owners22.06%
Inst Owner Change2.41%
Ins Owners2.04%
Ins Owner ChangeN/A
Market Cap23.72B
Analysts80
Price Target138.29 (40.14%)
Short Float %5.24%
Short Ratio3.93
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)188.14%
Min EPS beat(2)150.91%
Max EPS beat(2)225.36%
EPS beat(4)2
Avg EPS beat(4)73.79%
Min EPS beat(4)-62.82%
Max EPS beat(4)225.36%
EPS beat(8)5
Avg EPS beat(8)298.37%
EPS beat(12)8
Avg EPS beat(12)207.85%
EPS beat(16)12
Avg EPS beat(16)165.24%
Revenue beat(2)2
Avg Revenue beat(2)57.27%
Min Revenue beat(2)6.92%
Max Revenue beat(2)107.62%
Revenue beat(4)2
Avg Revenue beat(4)11.13%
Min Revenue beat(4)-56.98%
Max Revenue beat(4)107.62%
Revenue beat(8)2
Avg Revenue beat(8)-8.3%
Revenue beat(12)5
Avg Revenue beat(12)2.28%
Revenue beat(16)9
Avg Revenue beat(16)11.05%
PT rev (1m)-0.53%
PT rev (3m)-2.59%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10.95%
EPS NY rev (1m)-1.05%
EPS NY rev (3m)-55.57%
Revenue NQ rev (1m)11.11%
Revenue NQ rev (3m)-26.26%
Revenue NY rev (1m)-2.62%
Revenue NY rev (3m)-20.62%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.62
P/FCF N/A
P/OCF 100.99
P/B 1.08
P/tB 1.15
EV/EBITDA N/A
EPS(TTM)-3.62
EYN/A
EPS(NY)-6.29
Fwd EYN/A
FCF(TTM)-1.15
FCFYN/A
OCF(TTM)0.98
OCFY0.99%
SpS12.94
BVpS91.32
TBVpS85.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.95%
ROE -3.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.9%
FCFM N/A
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
F-Score3
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 151.78%
Cap/Sales 16.44%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.45
Quick Ratio 7.34
Altman-Z 6.06
F-Score3
WACC7.12%
ROIC/WACCN/A
Cap/Depr(3y)277.19%
Cap/Depr(5y)250.97%
Cap/Sales(3y)12.34%
Cap/Sales(5y)11.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-780.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-32.06%
EPS Next Y-92.43%
EPS Next 2Y-41.48%
EPS Next 3Y-22.99%
EPS Next 5Y10.72%
Revenue 1Y (TTM)-27.96%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%-2.56%
Revenue Next Year-22.85%
Revenue Next 2Y-8.27%
Revenue Next 3Y-5.15%
Revenue Next 5Y5.22%
EBIT growth 1Y-232.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-3.69%
EBIT Next 3Y-5.89%
EBIT Next 5Y21.97%
FCF growth 1Y-105.24%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-96.13%
OCF growth 3Y-38.43%
OCF growth 5YN/A